Bayer Gets German Panel Request for Data on Cancer Drug Stivarga
This article is for subscribers only.
Bayer AG will have to share more data about the quality of life for patients who take its costly new cancer medicine Stivarga after a request from a German panel that makes coverage decisions for public insurers.
The Federal Joint Committee voted to give the company 18 months to provide the new data, which could come in the form of a clinical trial. Pending those results, the panel made a temporary ruling today that Stivarga offers patients a slight added benefit compared to existing therapy that costs less than a quarter as much.